PVI
ESPR

Pura Vida Investments’s Esperion Therapeutics ESPR Stock Holding History

Pura Vida Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-34,500
Closed -$2.14M – 71
2015
Q2 		$2.14M Buy
+34,500
New +$3.38M 1.09% 46

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Pura Vida Investments's ESPR Position: Q1 2023 in Review

Pura Vida Investments sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 308,313 shares — an estimated $1.92M sold.

Pura Vida Investments first reported a position in ESPR in Q4 2014 and held it in 5 quarters. The position peaked at $2.23M in Q3 2022. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Pura Vida Investments reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 308,313 Esperion Therapeutics shares in Q1 2023, an estimated $1.92M.
  • Pura Vida Investments first reported a position in Esperion Therapeutics in Q4 2014 and held it in 5 quarters.
  • Pura Vida Investments's Esperion Therapeutics position peaked at $2.23M in Q3 2022.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.